Enanta Pharmaceuticals INC (ENTA) Holder Great Point Partners LLC Trimmed Its Holding as Share Value Rose

Investors sentiment decreased to 1.21 in Q4 2018. Its down 0.08, from 1.29 in 2018Q3. It dived, as 26 investors sold ENTA shares while 47 reduced holdings. 26 funds opened positions while 62 raised stakes. 16.77 million shares or 3.84% more from 16.15 million shares in 2018Q3 were reported. Cubist Systematic Strategies Ltd Co reported 3,321 shares. First Manhattan owns 679,734 shares. Victory Cap Management owns 2,979 shares. Louisiana State Employees Retirement holds 0.02% or 5,881 shares in its portfolio. Los Angeles Capital Management Equity Research Inc has invested 0% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Principal Inc holds 137,169 shares. Marshall Wace Ltd Liability Partnership owns 151,891 shares for 0.11% of their portfolio. Hussman Strategic Advsr Incorporated, a Maryland-based fund reported 10,000 shares. Origin Asset Llp reported 0.02% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Glenmede Trust Co Na owns 57 shares or 0% of their US portfolio. Virginia Retirement Systems Et Al stated it has 0.01% of its portfolio in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). State Board Of Administration Of Florida Retirement Systems has invested 0% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Matarin Cap Lc owns 209,865 shares. Blackrock stated it has 0.01% of its portfolio in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Deutsche Commercial Bank Ag reported 76,836 shares or 0% of all its holdings.

Since September 20, 2018, it had 0 insider purchases, and 5 sales for $3.32 million activity. Shares for $696,102 were sold by CARTER BRUCE L A on Monday, February 11. Adda Nathalie sold $396,036 worth of stock or 4,155 shares. 3,270 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) shares with value of $311,562 were sold by Gardiner Nathaniel S..

Great Point Partners Llc decreased its stake in Enanta Pharmaceuticals Inc (ENTA) by 31.81% based on its latest 2018Q4 regulatory filing with the SEC. Great Point Partners Llc sold 66,919 shares as the company’s stock rose 22.87% with the market. The hedge fund held 143,481 shares of the health care company at the end of 2018Q4, valued at $10.16 million, down from 210,400 at the end of the previous reported quarter. Great Point Partners Llc who had been investing in Enanta Pharmaceuticals Inc for a number of months, seems to be less bullish one the $1.97 billion market cap company. The stock increased 0.31% or $0.31 during the last trading session, reaching $101.24. About 161,745 shares traded. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has risen 33.26% since March 17, 2018 and is uptrending. It has outperformed by 28.89% the S&P500.

Great Point Partners Llc, which manages about $935.83M and $791.19M US Long portfolio, upped its stake in Five Prime Therapeutics Inc (NASDAQ:FPRX) by 750,656 shares to 2.40M shares, valued at $22.31M in 2018Q4, according to the filing. It also increased its holding in Tg Therapeutics Inc (NASDAQ:TGTX) by 1.05 million shares in the quarter, for a total of 3.00 million shares, and has risen its stake in Ptc Therapeutics Inc (NASDAQ:PTCT).

Analysts await Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to report earnings on May, 14. They expect $-0.07 earnings per share, down 111.48 % or $0.68 from last year’s $0.61 per share. After $1.25 actual earnings per share reported by Enanta Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -105.60 % negative EPS growth.

More notable recent Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) news were published by: Seekingalpha.com which released: “Enanta Pharma FQ4 top line down 12%; earnings down 25%; shares down 1% after hours – Seeking Alpha” on November 26, 2018, also Nasdaq.com with their article: “After-Hours Earnings Report for November 26, 2018 : ENTA, BKE, MTSC, GSM – Nasdaq” published on November 26, 2018, Seekingalpha.com published: “Enanta Pharmaceuticals FQ3 revenue up 84% – Seeking Alpha” on February 06, 2019. More interesting news about Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) were released by: Nasdaq.com and their article: “Notable Friday Option Activity: ENTA, LULU, CBRL – Nasdaq” published on March 08, 2019 as well as Globenewswire.com‘s news article titled: “Factors of Influence in 2019, Key Indicators and Opportunity within BCE, Nektar Therapeutics, Hormel Foods, Enanta Pharmaceuticals, MongoDB, and Regal Beloit — New Research Emphasizes Economic Growth – GlobeNewswire” with publication date: February 15, 2019.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Institutional Positions Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.